A single center, open-labeled, pilot study to evaluate the safety and efficacy of cardiac cycle-synchronized electrical lower limb muscle stimulation therapy for cardiovascular disease - Cardiac cycle-synchronized electrical lower limb muscle stimulation therapy for cardiovascular disease

Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine0 sites30 target enrollmentApril 4, 2017

Conditionsatent heart failure (NYHA class: II-III), ischemic heart disease (CCS class: II-III), peripheral artery disease (Fontaine class: II-IV), pulmonary artery hypertension (WHO class: II-III), and healthy adult

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: atent heart failure (NYHA class: II-III), ischemic heart disease (CCS class: II-III), peripheral artery disease (Fontaine class: II-IV), pulmonary artery hypertension (WHO class: II-III), and healthy adult
Sponsor: Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 4, 2017

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Hard fitting of the equipment of this study Skin, muscle, or bone disease in limbs Implantation of cardiac pacemaker Uncontrolled hypertension Blood pressure at rest\>160/100 mmHg Uncontrolled arrhythmia Arrhythmia with unstable hemodynamics Pregnancy Malignant disease on no\-remission

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting

Phase 1

Biocompatible & Biodegradable Polymeric Skin Grafts for WoundsHealth Condition 1: T758- Other specified effects of external causes

CTRI/2020/11/029284SASTRA Deemed University

Active, Not Recruiting

Phase 1

A pilot study to assess the efficacy and safety of CBD oral solution in addition to standard treatment for pediatric subjects with Developmental and Epileptic EncephalopathyDevelopmental and Epileptic Encephalopathy (DEE)MedDRA version: 20.0Level: PTClassification code 10077380Term: Epileptic encephalopathySystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]

EUCTR2019-001633-14-ITIRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA20

Withdrawn

Phase 1

A SINGLE CENTER OPEN-LABEL PILOT STUDY TO EVALUATE THE TOLERABILITY AND SAFETY OF A SYNTHETIC SOFT TISSUE IMPLANT MATERIAL IN THE SKIN OF NORMAL VOLUNTEERSTolerability and safety of a new synthetic soft tissue implant material for soft tissue augmentation in healthy volunteers.Surgery - Other surgery

ACTRN12607000223437COSMETREND PTY LTD8

Recruiting

Phase 1

A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

CTIS2023-507137-24-00Institute Of Tropical Medicine78

Active, Not Recruiting

N/A

A single center, open, pilot study to evaluate the pharmacokinetic profile of a new galenic formulation of an Ambroxol-Hydrochloride (Ambroxol-HCl) spray: Ambroxol CYATHUS” 50 mg/mL Oral Spray, administered in a single dose of 30 mg Ambroxol-HCl to healthy male volunteersMedDRA version: 8.1Level: LLTClassification code 10006440Term: Bronchial obstruction

EUCTR2006-005291-41-ATCYATHUS Exquirere PharmaforschungsGmbH